679 Participants Needed

IcoSema for Type 2 Diabetes

Recruiting at 245 trial locations
NN
Overseen ByNovo Nordisk
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Novo Nordisk A/S
Must be taking: Basal insulin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. It aims to see if IcoSema can control blood sugar better than the current daily treatments. Participants will receive either IcoSema or the standard daily injections. The study will take place over several months, and participants will wear a sensor to monitor their blood sugar levels.

Who Is on the Research Team?

CT

Clinical Transparency (dept. 1452)

Principal Investigator

Novo Nordisk A/S

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosed with type 2 diabetes mellitus 180 days or more before screening
HbA1c of 7.0-10.0 percentage (53.- 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening
Treated with once daily or twice-daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20-80 units/day 90 days or more before screening
See 3 more

Exclusion Criteria

Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non dilated examination.
Any episodes of diabetic ketoacidosis within 90 days before screening. As declared by the participant or in the medical records
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either IcoSema once weekly or insulin glargine daily with insulin aspart for 52 weeks

52 weeks
Weekly injections for IcoSema, daily injections for insulin glargine and insulin aspart

Monitoring

Participants wear a continuous glucose monitoring sensor for 8 weeks at the beginning and 4 weeks at the end of the study

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • IcoSema
  • Insulin aspart
  • Insulin glargine
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: IcoSemaExperimental Treatment1 Intervention
Participants will receive once weekly subcutaneous (s.c) injections of IcoSema during the 52-week treatment period.
Group II: Insuling glargine/insulin aspartActive Control2 Interventions
Participants will receive subcutaneous (s.c) injections of insulin glargine once daily combined with 2-4 times daily injections of insulin aspart.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novo Nordisk A/S

Lead Sponsor

Trials
1,578
Recruited
3,813,000+
Lars Fruergaard Jørgensen profile image

Lars Fruergaard Jørgensen

Novo Nordisk A/S

Chief Executive Officer since 2017

MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark

Martin Holst Lange profile image

Martin Holst Lange

Novo Nordisk A/S

Chief Medical Officer since 2021

MD from University of Copenhagen

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security